Your browser doesn't support javascript.
loading
Long-term behavioral symptom clusters among survivors of early-stage breast cancer. development and validation of a predictive model.
Pagliuca, Martina; Havas, Julie; Thomas, Emilie; Drouet, Youenn; Soldato, Davide; Franzoi, Maria Alice; Ribeiro, Joana; Chiodi, Camila K; Gillanders, Emma; Pistilli, Barbara; Menvielle, Gwenn; Joly, Florence; Lerebours, Florence; Rigal, Olivier; Petit, Thierry; Giacchetti, Sylvie; Dalenc, Florence; Wassermann, Johanna; Arsene, Olivier; Martin, Anne Laure; Everhard, Sibille; Tredan, Olivier; Boyault, Sandrine; De Laurentiis, Michelino; Viari, Alain; Deleuze, Jean Francois; Bertaut, Aurelie; André, Fabrice; Vaz-Luis, Ines; Di Meglio, Antonio.
Afiliação
  • Pagliuca M; Cancer Survivorship Research Group, INSERM U981, Gustave Roussy, Villejuif, France.
  • Havas J; Departement of Breast and Thoracic Oncology, Division of Breast Medical Oncology, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Napoli, Italia.
  • Thomas E; Cancer Survivorship Research Group, INSERM U981, Gustave Roussy, Villejuif, France.
  • Drouet Y; Labex DEV2CAN, Institut Convergence Plascan, Centre Léon Bérard, Gilles Thomas Bioinformatics Platform, UMR INSERM 1052, CNRS 5286, Université Claude Bernard, Lyon 1, Lyon, France.
  • Soldato D; Labex DEV2CAN, Institut Convergence Plascan, Centre Léon Bérard, Gilles Thomas Bioinformatics Platform, UMR INSERM 1052, CNRS 5286, Université Claude Bernard, Lyon 1, Lyon, France.
  • Franzoi MA; Cancer Survivorship Research Group, INSERM U981, Gustave Roussy, Villejuif, France.
  • Ribeiro J; Cancer Survivorship Research Group, INSERM U981, Gustave Roussy, Villejuif, France.
  • Chiodi CK; Cancer Survivorship Research Group, INSERM U981, Gustave Roussy, Villejuif, France.
  • Gillanders E; Cancer Survivorship Research Group, INSERM U981, Gustave Roussy, Villejuif, France.
  • Pistilli B; Cancer Survivorship Research Group, INSERM U981, Gustave Roussy, Villejuif, France.
  • Menvielle G; Medical Oncology Department, INSERM U981, Gustave Roussy, Villejuif, France.
  • Joly F; Cancer Survivorship Research Group, INSERM U981, Gustave Roussy, Villejuif, France.
  • Lerebours F; Clinical Research Depatment, Inserm U1086 Anticipe, Centre Francois Baclesse, University UniCaen, Caen, France.
  • Rigal O; Medical Oncology Department, Institut Curie Saint Cloud, Saint Cloud, France.
  • Petit T; Medical Oncology Department, Centre Henri Becquerel, Rouen, France.
  • Giacchetti S; Medical Oncology Department, Institute of Cancer Strasbourg (ICANS), Strasbourg, France.
  • Dalenc F; Department of Breast Disease, APHP, University Hospital Saint Louis, Senopole, Paris, France.
  • Wassermann J; Medical Oncology Department, Oncopole Claudius Regaud, Institut Universitaire du Cancer, Toulouse, France.
  • Arsene O; Medical Oncology Department, Pitié Salpêtrière University Hospital, Cancer University Institute, AP-HP, Paris, France.
  • Martin AL; Medical Oncology Department, Centre Hospitalier de Blois, Blois, France.
  • Everhard S; Direction des Data et des Partenariats, UNICANCER, Paris, France.
  • Tredan O; Direction des Data et des Partenariats, UNICANCER, Paris, France.
  • Boyault S; Labex DEV2CAN, Institut Convergence Plascan, Centre Léon Bérard, Gilles Thomas Bioinformatics Platform, UMR INSERM 1052, CNRS 5286, Université Claude Bernard, Lyon 1, Lyon, France.
  • De Laurentiis M; Labex DEV2CAN, Institut Convergence Plascan, Centre Léon Bérard, Gilles Thomas Bioinformatics Platform, UMR INSERM 1052, CNRS 5286, Université Claude Bernard, Lyon 1, Lyon, France.
  • Viari A; Departement of Breast and Thoracic Oncology, Division of Breast Medical Oncology, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Napoli, Italia.
  • Deleuze JF; Labex DEV2CAN, Institut Convergence Plascan, Centre Léon Bérard, Gilles Thomas Bioinformatics Platform, UMR INSERM 1052, CNRS 5286, Université Claude Bernard, Lyon 1, Lyon, France.
  • Bertaut A; Centre National de Recherche en Génomique Humaine CNRGH-CEA, Laboratory of Excellence in Medical Genomics, GENMED, Évry-Courcouronnes, France.
  • André F; Unit of Methodology and Biostatistics, George-François Leclerc Cancer Center, Dijon, France.
  • Vaz-Luis I; Cancer Survivorship Research Group, INSERM U981, Gustave Roussy, Villejuif, France.
  • Di Meglio A; Cancer Survivorship Research Group, INSERM U981, Gustave Roussy, Villejuif, France.
J Natl Cancer Inst ; 2024 Sep 09.
Article em En | MEDLINE | ID: mdl-39250750
ABSTRACT

BACKGROUND:

Fatigue, cognitive impairment, anxiety, depression, and sleep disturbance are cancer-related behavioral symptoms (CRBS) that may persist years after early-stage breast cancer (BC), affecting quality of life. We aimed at generating a predictive model of long-term CRBS clusters among BC survivors four years post-diagnosis.

METHODS:

Patients with early-stage BC were included from the CANcer TOxicity (NCT01993498). Our outcome was the proportion of patients reporting CRBS clusters four years post-diagnosis (≥3 severe CRBS). Predictors, including clinical, behavioral, and treatment-related characteristics, Behavioral Symptoms Score (BSS; 1 point per severe CRBS at diagnosis) and a pro-inflammatory cytokine (IL-1b, IL-6, TNFα)-genetic risk score, were tested using multivariable logistic regression, implementing bootstrapped Augmented Backwards Elimination. A two-sided p-value < 0.05 defined statistical significance.

RESULTS:

In the development cohort (N = 3555), 642 patients (19.0%) reported a cluster of CRBS at diagnosis and 755 (21.2%) did so four years post-diagnosis. Younger age (adjusted Odds Ratio [aOR] for 1-year decrement 1.012; 95% Confidence Interval [CI] 1.003-1.020); previous psychiatric disorders (aOR vs no 1.27; 95% CI 1.01-1.60); and BSS (aOR ranged from 2.17 [1.66-2.85] for BSS = 1 vs 0 to 12.3 [7.33-20.87] for BSS = 5 vs 0) were predictors of reporting a cluster of CRBS (AUC 0.73 [95%CI 0.71-0.75]). Genetic risk score was not predictive of CRBS. Results were confirmed in the validation cohort (N = 1533).

CONCLUSION:

Younger patients with previous psychiatric disorders and higher baseline symptom burden have greater risk of long-term clusters of CRBS. Our model might be implemented in clinical pathways to improve management and test the effectiveness of risk mitigation interventions among breast cancer survivors.

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: J Natl Cancer Inst Ano de publicação: 2024 Tipo de documento: Article País de afiliação: França

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: J Natl Cancer Inst Ano de publicação: 2024 Tipo de documento: Article País de afiliação: França